Celine Pallaud
Overview
Explore the profile of Celine Pallaud including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
911
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
OFarrell A, Evans R, Silvola J, Miller I, Conroy E, Hector S, et al.
PLoS One
. 2017 Jan;
12(1):e0169964.
PMID: 28129334
Sunitinib is a tyrosine kinase inhibitor approved for the treatment of multiple solid tumors. However, cardiotoxicity is of increasing concern, with a need to develop rational mechanism driven approaches for...
12.
Dummer R, Guminski A, Gutzmer R, Dirix L, Lewis K, Combemale P, et al.
J Am Acad Dermatol
. 2016 Apr;
75(1):113-125.e5.
PMID: 27067394
Background: The hedgehog pathway inhibitor sonidegib demonstrated meaningful tumor shrinkage in more than 90% of patients with locally advanced basal cell carcinoma (BCC) or metastatic BCC in the BCC Outcomes...
13.
Migden M, Guminski A, Gutzmer R, Dirix L, Lewis K, Combemale P, et al.
Lancet Oncol
. 2015 May;
16(6):716-28.
PMID: 25981810
Background: Patients with advanced basal cell carcinoma have limited treatment options. Hedgehog pathway signalling is aberrantly activated in around 95% of tumours. We assessed the antitumour activity of sonidegib, a...
14.
Pallaud C, Reck M, Juhasz E, Szima B, Yu C, Burdaeva O, et al.
Lung Cancer
. 2014 Aug;
86(1):67-72.
PMID: 25154982
Objectives: ABIGAIL, a phase II, randomized, open-label, multicenter study evaluated the correlation between biomarkers and best overall response (BOR) to bevacizumab with chemotherapy in patients with advanced or recurrent non-small-cell...
15.
de Haas S, Delmar P, Bansal A, Moisse M, Miles D, Leighl N, et al.
Angiogenesis
. 2014 Jul;
17(4):909-20.
PMID: 25012543
Background: Despite extensive translational research, no validated biomarkers predictive of bevacizumab treatment outcome have been identified. Methods: We performed a meta-analysis of individual patient data from six randomized phase III...
16.
Mok T, Gorbunova V, Juhasz E, Szima B, Burdaeva O, Orlov S, et al.
J Thorac Oncol
. 2014 May;
9(6):848-55.
PMID: 24807156
Introduction: Avastin Biomarkers In lunG And 3D Innovative anaLysis (ABIGAIL), which is a phase II, open-label, randomized study, investigated correlations between biomarkers and best overall response to bevacizumab plus platinum-doublet...
17.
Lambrechts D, Moisse M, Delmar P, Miles D, Leighl N, Escudier B, et al.
Angiogenesis
. 2014 Feb;
17(3):685-94.
PMID: 24558090
Purpose: There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We combined biomarker data from six phase III trials of bevacizumab to assess whether genetic variation in...
18.
Cameron D, Brown J, Dent R, Jackisch C, Mackey J, Pivot X, et al.
Lancet Oncol
. 2013 Aug;
14(10):933-42.
PMID: 23932548
Background: The addition of bevacizumab to chemotherapy improves progression-free survival in metastatic breast cancer and pathological complete response rates in the neoadjuvant setting. Micrometastases are dependent on angiogenesis, suggesting that...
19.
Gianni L, Romieu G, Lichinitser M, Serrano S, Mansutti M, Pivot X, et al.
J Clin Oncol
. 2013 Apr;
31(14):1719-25.
PMID: 23569311
PURPOSE The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated first-line bevacizumab-containing therapy for human epidermal growth factor...